Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Total 13F shares
-
81,619,644
-
Share change
-
-2,519,721
-
Total reported value
-
$248,123,678
-
Put/Call ratio
-
246%
-
Price per share
-
$3.04
-
Number of holders
-
169
-
Value change
-
-$34,475,559
-
Number of buys
-
82
-
Number of sells
-
105
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q4 2024
As of 31 Dec 2024,
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) was held by
169 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
81,619,644 shares.
The largest 10 holders included
BlackRock, Inc., Beryl Capital Management LLC, VANGUARD GROUP INC, ODDO BHF ASSET MANAGEMENT SAS, FIL Ltd, ALLIANCEBERNSTEIN L.P., Squarepoint Ops LLC, Magnetar Financial LLC, STATE STREET CORP, and ALPINE ASSOCIATES MANAGEMENT INC..
This page lists
169
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.